Hasil Pencarian - Herbert Struemper

  • Menampilkan 1 - 6 hasil dari 6
Perbaiki Hasil
  1. 1
    Reductions in circulating B cell subsets and immunoglobulin G levels with long-term belimumab treatment in patients with SLE

    Reductions in circulating B cell subsets and immunoglobulin G levels with long-term belimumab treatment in patients with SLE oleh William Stohl, Milena Kurtinecz, David A Roth, Herbert Struemper, William W Freimuth, Lisa Edwards

    Diterbitkan 2022-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Population pharmacokinetics of belantamab mafodotin, a BCMA‐targeting agent in patients with relapsed/refractory multiple myeloma

    Population pharmacokinetics of belantamab mafodotin, a BCMA‐targeting agent in patients with relapsed/refractory multiple myeloma oleh Chetan Rathi, Jon Collins, Herbert Struemper, Joanna Opalinska, Roxanne C. Jewell, Geraldine Ferron‐Brady

    Diterbitkan 2021-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Longitudinal efficacy and safety modeling and simulation framework to aid dose selection of belantamab mafodotin for patients with multiple myeloma

    Longitudinal efficacy and safety modeling and simulation framework to aid dose selection of belantamab mafodotin for patients with multiple myeloma oleh Jon Collins, Martijn vanNoort, Chetan Rathi, Teun M. Post, Herbert Struemper, Roxanne C. Jewell, Geraldine Ferron‐Brady

    Diterbitkan 2023-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Manufacturing‐dependent change in biological activity of the TLR4 agonist GSK1795091 and implications for lipid A analog development

    Manufacturing‐dependent change in biological activity of the TLR4 agonist GSK1795091 and implications for lipid A analog development oleh Neeltje Steeghs, Aaron R. Hansen, Glenn J. Hanna, Elena Garralda, Haeseong Park, James Strauss, Michael Adam, Gossett Campbell, Jennifer Carver, Rachael Easton, Katherine Mays, Peter Skrdla, Herbert Struemper, Michael L. Washburn, Christopher Matheny, Sarina A. Piha‐Paul

    Diterbitkan 2022-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study

    Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study oleh Anders Österborg, Roxanne C. Jewell, Swami Padmanabhan-Iyer, Thomas J. Kipps, Jiří Mayer, Stephan Stilgenbauer, Cathy D. Williams, Andrzej Hellmann, Richard R. Furman, Tadeusz Robak, Peter Hillmen, Marek Trnêný, Martin J.S. Dyer, Magdalena Piotrowska, Tomas Kozak, Ira V. Gupta, Jennifer L. Phillips, Nancy Goldstein, Herbert Struemper, Nedjad Losic, Steen Lisby, William G. Wierda

    Diterbitkan 2015-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)

    First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1) oleh Stephane Champiat, Aurélien Marabelle, Anna Spreafico, Mehmet Altan, Todd M Bauer, Osama Rahma, Karen A Autio, Neeta Somaiah, Meredith McKean, Aaron R Hansen, Jan H M Schellens, Willeke Ros, F Stephen Hodi, Jeffrey S Weber, John V Heymach, Herbert Struemper, Sandrine Aspeslagh, Daniel C Cho, Jennifer K Litton, Axel Hoos, Vincent K Lam, Emmett V Schmidt, Sophie Postel-Vinay, Frans L Opdam, Elaine M Paul, Christoph M Ahlers, Helen Zhou, Shelby A Gorman, Maura Watmuff, Kaitlin M Yablonski, Niranjan Yanamandra, Michael J Chisamore

    Diterbitkan 2023-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: